FDA Approves Novartis' Adakveo for Some Patients with Sickle Cell Complications

Date : 11/15/2019 @ 9:14PM
Source : Dow Jones News
Stock : Novartis AG (NVS)
Quote : 95.89  0.35 (0.37%) @ 3:00PM

FDA Approves Novartis' Adakveo for Some Patients with Sickle Cell Complications

Novartis (NYSE:NVS)
Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more Novartis Charts.
   By Stephen Nakrosis 

The U.S. Food and Drug Administration said Friday it approved Adakveo, or crizanlizumab-tmca, to treat certain complications arising in patients with sickle cell disease.

The approval was granted to Novartis AG (NVS), and is the first FDA approval for a "targeted therapy to treat patients with painful complication of sickle cell disease," the agency said.

"Adakveo is the first targeted therapy approved for sickle cell disease, specifically inhibiting selectin, a substance that contributes to cells sticking together and leads to vaso-occlusive crisis," said Richard Pazdur, director of the FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA's Center for Drug Evaluation and Research.

"The Adakveo approval was based on the results of a randomized clinical trial enrolling 198 patients with sickle cell disease with a history of vaso-occlusive crisis," the FDA said.


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

November 15, 2019 15:59 ET (20:59 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest NVS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.